A Prospective Cohort Study on Colorectal Cancer Screening in Community Population
Colorectal Cancer Screening Cohort Study in Shougang Community Population Based on Polygene Methylation Detection Technology
Singlera Genomics Inc.
18,000 participants
Jul 9, 2022
OBSERVATIONAL
Conditions
Summary
This study will validate the real world results of polygene methylation detection in colorectal cancer in a large prospective community cohort. In this study, questionnaire survey and polygene methylation detection technology of colorectal cancer were used as preliminary screening methods, and colonoscopy was used as further validation examination method to screen colorectal cancer and precancerous lesions. The diagnosis and outcome of all lesions were based on colonoscopy and pathological examination.
Eligibility
Inclusion Criteria4
- Chronological age ≥40 years;
- Full capacity for action;
- After enrollment, the participants were able to complete the Colorectal Cancer Risk Factor Assessment Questionnaire and the annual follow-up interviews;
- In the course of the study, the information related to tumor diagnosis in other hospitals can be timely fed back to the researchers;
Exclusion Criteria8
- History of colorectal cancer and other malignant tumors;
- Previous colorectal resection;
- undergoing any cancer-related treatment;
- Patients who have received major surgical treatment such as blood transfusion or transplantation within 3 months;
- Participate in other interventional clinical investigators within 3 months;
- Pregnant or lactating women;
- Have autoimmune disease, hereditary disease, mental illness/disability, etc
- Poor compliance, unable to complete the study.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05485077